Cytokinetics (NASDAQ:CYTK) Stock Price Down 7.7% Following Weak Earnings

Cytokinetics, Incorporated (NASDAQ:CYTK)’s share price dropped 7.7% during trading on Wednesday after the company announced weaker than expected quarterly earnings. The company traded as low as $64.51 and last traded at $64.6990. Approximately 667,422 shares changed hands during mid-day trading, a decline of 61% from the average daily volume of 1,698,679 shares. The stock had previously closed at $70.10.

The biopharmaceutical company reported ($1.50) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The company had revenue of $17.76 million for the quarter, compared to analysts’ expectations of $8.02 million. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.26) earnings per share.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: HC Wainwright reiterates a “Buy” and models near‑term quarterly EPS (Q1: -$1.57, Q2: -$1.61, Q4: -$1.89) while assigning a $136 price target — a substantial upside that supports longer‑term investor interest. HC Wainwright estimates
• Positive Sentiment: Analysts have been raising price targets: Citizens JMP to $96 (market outperform), Leerink Partners to $84 (outperform), and Needham to $85 (buy) — these upgrades add upward pressure on sentiment. Benzinga price target coverage
• Positive Sentiment: Zacks notes Cytokinetics is advancing Myqorzo launch plans after FDA activity and highlights a ~$1.22B cash position, which supports funding for commercialization and 2026 catalysts. Myqorzo launch & cash runway
• Positive Sentiment: Retail/permissioned coverage and bullish opinion pieces (e.g., Villanovan profile) are promoting a buy case based on pipeline and commercialization upside. Why Cytokinetics Is a Buy
• Neutral Sentiment: Q4 earnings call and transcript coverage are available for deeper read‑throughs of management commentary on margins, SG&A, and launch timing (useful for assessing execution risk). Earnings call transcript (InsiderMonkey) Earnings transcript (Seeking Alpha) Earnings transcript (Yahoo)
• Neutral Sentiment: Reported short‑interest data appears anomalous/zero in the latest release, so there’s no clear short‑squeeze signal from those figures. (No actionable short‑pressure evidence.)
• Negative Sentiment: Q4 results showed a slightly wider-than-expected loss (EPS -$1.50 vs. estimate -$1.48) and higher expenses year‑over‑year — a near‑term negative that likely pressured the stock despite revenue outperformance. Q4 results coverage

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. B. Riley Financial lifted their price objective on Cytokinetics from $90.00 to $108.00 and gave the company a “buy” rating in a research report on Wednesday, January 21st. Citizens Jmp raised their price target on Cytokinetics from $88.00 to $96.00 and gave the stock a “market outperform” rating in a research note on Wednesday. Needham & Company LLC lifted their price target on Cytokinetics from $84.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday. Barclays started coverage on Cytokinetics in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $87.00 price target for the company. Finally, Morgan Stanley set a $90.00 price objective on shares of Cytokinetics in a research report on Thursday, January 8th. Seventeen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $88.83.

Insider Buying and Selling

In other Cytokinetics news, EVP Fady Ibraham Malik sold 2,200 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $61.24, for a total transaction of $134,728.00. Following the completion of the sale, the executive vice president owned 138,552 shares of the company’s stock, valued at $8,484,924.48. This represents a 1.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Andrew Callos sold 15,000 shares of the stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $61.93, for a total value of $928,950.00. Following the transaction, the executive vice president owned 50,440 shares in the company, valued at approximately $3,123,749.20. This trade represents a 22.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 151,385 shares of company stock worth $9,817,158. 2.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CYTK. Seven Fleet Capital Management LP acquired a new position in Cytokinetics during the 4th quarter worth $657,000. Alpine Global Management LLC acquired a new position in shares of Cytokinetics during the 4th quarter worth about $381,000. Pacer Advisors Inc. lifted its position in shares of Cytokinetics by 76.5% during the 4th quarter. Pacer Advisors Inc. now owns 27,783 shares of the biopharmaceutical company’s stock worth $1,765,000 after purchasing an additional 12,043 shares during the last quarter. Invesco Ltd. boosted its stake in Cytokinetics by 30.3% during the 4th quarter. Invesco Ltd. now owns 204,878 shares of the biopharmaceutical company’s stock valued at $13,018,000 after purchasing an additional 47,629 shares during the period. Finally, Corient Private Wealth LLC grew its holdings in Cytokinetics by 527.1% in the 4th quarter. Corient Private Wealth LLC now owns 30,184 shares of the biopharmaceutical company’s stock valued at $1,918,000 after buying an additional 25,371 shares during the last quarter.

Cytokinetics Stock Performance

The company has a market capitalization of $7.66 billion, a P/E ratio of -9.59 and a beta of 0.54. The company has a 50-day simple moving average of $64.21 and a 200 day simple moving average of $58.38.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.